Expanded Access Use of Ladiratuzumab Vedotin in Advanced Solid Tumors

Registration Number
NCT06362590
Lead Sponsor
Seagen Inc.
Brief Summary

The purpose of this study is to provide the option of Ladiratuzumab Vedotin treatment to eligible patients in studies SGNLVA-005.

Detailed Description

Not available

Recruitment & Eligibility

Status
AVAILABLE
Sex
Not specified
Target Recruitment
Not specified
Inclusion Criteria
Read More
Exclusion Criteria
Read More

Study & Design

Study Type
EXPANDED_ACCESS
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2024. All Rights Reserved by MedPath